Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

TPdsm: a method based on TabPFN for prediction of deleterious synonymous mutations.

Created on 26 Jul 2026

Authors

Bing Zeng, Min Hu, Zhonghui Cui, Siting Zhou, Weiwei Dai

Published in

Bioinformatics advances. Volume 6. Issue 1. Pages vbag194. Epub Jul 13, 2026.

Abstract

Assessing the deleteriousness of synonymous mutations is of considerable importance for understanding human health, and the development of corresponding prediction methods offers a rapid and efficient approach. However, the scarcity of training data remains a major bottleneck in building high-performance predictors for synonymous mutation deleteriousness. Herein, we present TPdsm, a novel method for predicting deleterious synonymous mutations.
TPdsm leverages TabPFN, a tabular foundation model specifically designed for small-sample prediction. The features are retrieved from CDsyn, a comprehensive database dedicated to deleterious synonymous mutation prediction. Our evaluation demonstrates that TPdsm delivers better predictive performance than a set of 14 current state-of-the-art predictors, as evidenced by its results across multiple independent testing datasets and real-world cases.
TPdsm is available on GitHub at https://github.com/Project4bz2023/TPdsm. The pre-computed score of TPdsm can be accessed at https://doi.org/10.5281/zenodo.18265619. The result can be queried at https://bingtseng-tpdsm.share.connect.posit.cloud/.

PMID:
42502480
Bibliographic data and abstract were imported from PubMed on 26 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement